Movement Alert｜Pharmaron Rises 6.02% in Regular Trading, H1 Earnings Preview Shows Strong Revenue Growth Amid CXO Sector Rally

Market Focus07-15

On July 15, Pharmaron rose 6.02% in regular trading, trading at HK$24.68/share, with turnover of HK$124 million.

The rally was driven by the company's H1 earnings preview disclosed on July 13 and continued momentum across the CXO sector. Pharmaron forecast H1 revenue of RMB 7.47-7.67 billion, up 16%-19% YoY, with attributable net profit of RMB 729-772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884-922 million, up 17%-22% YoY. The company highlighted newly signed orders growing over 30% YoY, with small-molecule CDMO orders surging over 50%. By mid-point estimates, Q2 revenue grew 19.38% YoY with sequential profit acceleration.

At the sector level, the CXO segment has sustained its rebound supported by strong orders and earnings, with the CRO index rallying 21.72% from June 8 to July 10. Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovery in global biopharma funding and robust CMC business growth prospects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1195364567?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195364567","market":"us","top_or_hot":-1,"title":"Movement Alert｜Pharmaron Rises 6.02% in Regular Trading, H1 Earnings Preview Shows Strong Revenue Growth Amid CXO Sector Rally","media":"Market Focus","content":"<p><p>On July 15, Pharmaron rose 6.02% in regular trading, trading at HK$24.68/share, with turnover of HK$124 million.</p><p>The rally was driven by the company's H1 earnings preview disclosed on July 13 and continued momentum across the CXO sector. Pharmaron forecast H1 revenue of RMB 7.47-7.67 billion, up 16%-19% YoY, with attributable net profit of RMB 729-772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884-922 million, up 17%-22% YoY. The company highlighted newly signed orders growing over 30% YoY, with small-molecule CDMO orders surging over 50%. By mid-point estimates, Q2 revenue grew 19.38% YoY with sequential profit acceleration.</p><p>At the sector level, the CXO segment has sustained its rebound supported by strong orders and earnings, with the CRO index rallying 21.72% from June 8 to July 10. Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovery in global biopharma funding and robust CMC business growth prospects.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pharmaron Rises 6.02% in Regular Trading, H1 Earnings Preview Shows Strong Revenue Growth Amid CXO Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pharmaron Rises 6.02% in Regular Trading, H1 Earnings Preview Shows Strong Revenue Growth Amid CXO Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Pharmaron rose 6.02% in regular trading, trading at HK$24.68/share, with turnover of HK$124 million.</p><p>The rally was driven by the company's H1 earnings preview disclosed on July 13 and continued momentum across the CXO sector. Pharmaron forecast H1 revenue of RMB 7.47-7.67 billion, up 16%-19% YoY, with attributable net profit of RMB 729-772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884-922 million, up 17%-22% YoY. The company highlighted newly signed orders growing over 30% YoY, with small-molecule CDMO orders surging over 50%. By mid-point estimates, Q2 revenue grew 19.38% YoY with sequential profit acceleration.</p><p>At the sector level, the CXO segment has sustained its rebound supported by strong orders and earnings, with the CRO index rallying 21.72% from June 8 to July 10. Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovery in global biopharma funding and robust CMC business growth prospects.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1195364567","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195364567","pubTimestamp":1784079996,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Pharmaron rose 6.02% in regular trading, trading at HK$24.68/share, with turnover of HK$124 million.The rally was driven by the company's H1 earnings preview disclosed on July 13 and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势提醒|康龙化成常规交易上涨 6.02%，上半年盈利预览显示 CXO 板块反弹中收入强劲增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On July 15, Pharmaron rose 6.02% in regular trading, trading at HK$24.68/share, with turnover of HK$124 million.The rally was driven by the company's H1 earnings preview disclosed on July 13 and continued momentum across the CXO sector. Pharmaron forecast H1 revenue of RMB 7.47-7.67 billion, up 16%-19% YoY, with attributable net profit of RMB 729-772 million, up 4%-10% YoY. Adjusted non-IFRS net profit is expected at RMB 884-922 million, up 17%-22% YoY. The company highlighted newly signed orders growing over 30% YoY, with small-molecule CDMO orders surging over 50%. By mid-point estimates, Q2 revenue grew 19.38% YoY with sequential profit acceleration.At the sector level, the CXO segment has sustained its rebound supported by strong orders and earnings, with the CRO index rallying 21.72% from June 8 to July 10. Daiwa recently initiated coverage with a Buy rating and HK$25.5 target price, citing recovery in global biopharma funding and robust CMC business growth prospects.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,preview","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195364567","isCrawlerRequest":true}